We are studying whether maridebart cafraglutide can improve heart failure symptoms and reduce hospital visits for people with heart failure and obesity. This trial compares the new treatment to a placebo alongside standard care.
Health conditions and diseases that the clinical trial is designed to study and treat.
Heart failure is a condition where the heart is unable to pump blood effectively, which can lead to symptoms like shortness of breath, fatigue, and fluid retention. In this case, it specifically refers to heart failure with preserved or mildly reduced ejection fraction, often associated with obesity.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.